Novo Nordisk A/ S stock (DK0060534915): Wegovy and Ozempic momentum after latest earnings

Novo Nordisk A/S has raised its 2024 outlook again on the back of booming demand for its obesity drug Wegovy and diabetes therapy Ozempic, while investing heavily in new capacity. What this means for the stock and for US-focused investors.

Novo Nordisk A/S has once more lifted its full-year 2024 guidance after reporting strong first-quarter results driven by obesity treatment Wegovy and diabetes drug Ozempic, according to a company release dated 05/02/2024 and follow-up coverage from major financial media on the same day (Novo Nordisk investor information as of 05/02/2024 and Reuters as of 05/02/2024). The company highlighted robust demand in the United States for its GLP?1 portfolio, confirming its position as one of the most closely watched healthcare stocks globally.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novo Nordisk
• Sector/industry: Pharmaceuticals, diabetes and obesity care
• Headquarters/country: Bagsværd, Denmark
• Core markets: North America, Europe, selected international markets
• Key revenue drivers: GLP?1 diabetes and obesity therapies, insulin products, rare disease treatments
• Home exchange/listing venue: Nasdaq Copenhagen (ticker: NOVO?B); US ADRs listed on NYSE (ticker: NVO)
• Trading currency: Danish krone in Copenhagen; US dollars for ADRs

Novo Nordisk A/S: core business model

Novo Nordisk focuses on chronic disease therapies, with a long-standing specialization in diabetes care and an increasingly strong presence in obesity treatment. The company develops and commercializes both injectable and oral medicines that target metabolic pathways, especially those involving the GLP?1 hormone. Over decades, it has built a global commercial footprint supported by manufacturing sites in Europe, the US and other regions.

The business model relies on high-volume, patent-protected medicines that serve large patient populations, particularly in markets with rising prevalence of obesity and type 2 diabetes such as the United States. While research and development spending is significant, the company benefits from scale in manufacturing and established relationships with healthcare providers, payers and pharmacy benefit managers. This combination has helped Novo Nordisk sustain margins despite pricing and reimbursement pressures that are common in the US pharmaceutical market.

In addition to diabetes and obesity, Novo Nordisk is active in rare endocrine disorders and hemophilia, although these segments are smaller compared with GLP?1 therapies. The firm uses its expertise in peptide and protein engineering to expand its pipeline, aiming to extend its leadership beyond current flagship products as they approach the later stages of their patent lives. For investors, this pipeline breadth and the company’s track record in converting candidates into commercial products are key parts of the equity story.

Main revenue and product drivers for Novo Nordisk A/S

The main growth engines for Novo Nordisk are its GLP?1 based products Ozempic for type 2 diabetes and Wegovy for obesity, both containing the active ingredient semaglutide. In the first quarter of 2024, the company reported strong sales momentum in these franchises, especially in the United States, where demand continued to exceed supply, according to its Q1 2024 results release on 05/02/2024 (Novo Nordisk financial results as of 05/02/2024). The company has been ramping up production capacity to address the constraints.

GLP?1 products are used both for blood sugar control in diabetes and, in higher doses or specific formulations, for weight management. Clinical data suggesting benefits beyond weight loss, such as cardiovascular risk reduction, have further increased physician interest and patient demand. This has helped Novo Nordisk expand its prescriber base and negotiate broader coverage with US insurers. However, the company also faces the challenge of keeping up with the rapid uptake, which requires substantial capital expenditure in new production lines and facilities.

Insulin products, once the dominant revenue stream, remain important but represent a declining share of total sales as GLP?1 therapies grow more quickly. Novo Nordisk still generates meaningful income from modern and long-acting insulins, especially in markets outside the US where GLP?1 adoption is slower. Rare disease therapies, including treatments for growth disorders and hemophilia, provide additional diversification. Over time, however, the investment narrative has increasingly centered on obesity and related indications, where the company sees a multiyear opportunity.

Recent earnings and guidance moves

In its Q1 2024 report published on 05/02/2024, Novo Nordisk posted strong revenue growth and raised its full-year guidance, citing continued demand for Wegovy and Ozempic in major markets. The company stated that sales growth was broad-based across regions but particularly strong in North America, reflecting higher volumes of GLP?1 prescriptions and expanded market access, according to its official earnings communication (Novo Nordisk investor information as of 05/02/2024). The guidance upgrade signaled management’s confidence in sustaining momentum through 2024.

Alongside the topline performance, Novo Nordisk highlighted continued investment in manufacturing capacity and research and development. The company has been dedicating significant resources to expand fill-and-finish operations and build new facilities, including projects in Denmark and the United States, to support long-term supply of Wegovy and related products. These investments can weigh on near-term margins but are aimed at securing the ability to meet demand and maintain market share as competitors step up efforts in the same therapeutic area.

From a financial perspective, the company’s balance between returning cash to shareholders through dividends and buybacks and funding its growth initiatives remains a focal point for market observers. While details around specific buyback volumes and dividend policies evolve over time, the general approach has been to maintain a shareholder-friendly capital allocation framework while keeping sufficient flexibility to support strategic projects. Analysts in major financial centers continue to monitor how incremental guidance changes translate into expectations for earnings per share and free cash flow over the medium term.

Industry trends and competitive position

Novo Nordisk operates in a global pharmaceutical industry that is increasingly focused on chronic metabolic conditions and their long-term health and economic impact. The rise in obesity and type 2 diabetes prevalence, particularly in the United States, Europe and emerging markets, has created strong demand for effective and convenient therapies. GLP?1 agonists have emerged as a central treatment modality, and Novo Nordisk is at the forefront of this trend due to its early investment and clinical development in this area, as highlighted in multiple industry analyses over the last few years (Reuters as of 02/01/2024).

Competition is intensifying, though, with large pharmaceutical peers advancing their own GLP?1 and combination therapies for both diabetes and obesity. In the US, rival products and pipeline candidates are competing for formulary placement and physician attention. This dynamic creates a moving landscape for pricing, reimbursement and market share, where product differentiation through efficacy, safety profile and mode of administration becomes critical. Novo Nordisk’s early mover advantage and breadth of clinical data give it a strong starting point, but sustaining that position will require continued innovation.

Beyond GLP?1 based drugs, broader industry trends such as value-based healthcare, increasing pressure from payers to justify drug prices, and scrutiny from regulators and policymakers play a role in shaping the company’s outlook. Discussions around the affordability of obesity treatments and their long-term benefits for healthcare systems are particularly relevant in the United States, where healthcare expenditures linked to obesity-related conditions are high. Novo Nordisk’s ability to demonstrate outcomes and engage with stakeholders on these issues is likely to influence both adoption and policy frameworks over time.

Why Novo Nordisk A/S matters for US investors

For US investors, Novo Nordisk is accessible through American Depositary Receipts listed on the New York Stock Exchange under the ticker NVO, providing exposure to a European-based healthcare leader with significant revenue derived from the US market. The United States is a key growth engine, especially for Wegovy and Ozempic, due to high obesity and diabetes rates and the willingness of healthcare systems and insurers to reimburse innovative therapies under certain conditions, according to sector reports and company disclosures (Novo Nordisk investors as of 03/15/2024).

From a portfolio construction perspective, Novo Nordisk provides exposure to themes such as chronic disease management, obesity care and biopharmaceutical innovation, which some investors consider structural growth areas. The stock is often compared with large US-based pharmaceutical and biotech names and may serve as a diversifier within a healthcare allocation. Its performance can be influenced by factors specific to the US market, including regulatory decisions, reimbursement trends, competitive launches and macroeconomic conditions affecting healthcare spending.

US-focused investors also pay attention to currency effects, as Novo Nordisk reports in Danish krone while the ADRs trade in US dollars. Movements in exchange rates between the dollar and the krone can impact reported results and ADR valuations, even when underlying operational performance is stable. In addition, policy developments such as potential drug pricing reforms or changes in obesity treatment coverage under public and private insurance programs represent important variables for the company’s longer-term US revenue trajectory.

Conclusion

Novo Nordisk A/S has reinforced its position as a leading player in diabetes and obesity care, underlined by its Q1 2024 results and upgraded full-year guidance. Strong demand for Wegovy and Ozempic, especially in the United States, continues to shape the company’s growth profile, while capacity investments aim to keep supply aligned with rising prescriptions. At the same time, investors need to consider competitive dynamics in GLP?1 therapies, potential policy changes around drug pricing and reimbursement, and the long-term requirement for innovation as current products age. Overall, Novo Nordisk remains at the center of a structural healthcare trend that is closely watched by US and global market participants.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.